Intrahepatic Bile Duct Injury as a Hepatic Immune-Related Adverse Event after Immune-Checkpoint Inhibitor Treatment

Abstract The increased use of immune-checkpoint inhibitors to treat various types of cancer has increased the incidence of immune-related adverse events (irAEs). Hepatic irAEs are frequent and can lead to serious conditions. Among the various types of hepatic irAEs reported to date, bile duct injury...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in gastroenterology 2021-07, Vol.15 (2), p.645-651
Main Authors: Murayama, Aiko, Tajiri, Kazuto, Nakaya, Atsuko, Ito, Hiroyuki, Hayashi, Yuka, Entani, Toshiki, Nagata, Kohei, Tanaka, Shinichi, Hamashima, Takeru, Yasuda, Ichiro
Format: Article
Language:English
Subjects:
Antibodies
Bile ducts
Biopsy
Case and Review
Case reports
Cholangitis
Cytokeratin
cytokeratin-7
Cytomegalovirus
Epstein-Barr virus
Gallbladder diseases
Hepatitis
immune-checkpoint inhibitors
immune-related adverse events
Infections
Liver
Lymphocytes
mycophenolate mofetil
Patients
Steroids
Ultrasonic imaging
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The increased use of immune-checkpoint inhibitors to treat various types of cancer has increased the incidence of immune-related adverse events (irAEs). Hepatic irAEs are frequent and can lead to serious conditions. Among the various types of hepatic irAEs reported to date, bile duct injury has been shown refractory to steroid treatment. This study describes 2 patients with hepatic irAEs manifesting as intrahepatic bile duct injury. Immunostaining with antibodies to both CD8 and cytokeratin-7 was useful for the diagnosis, and both patients were refractory to steroid treatment. Prompt diagnosis and active immunosuppressive therapies are required in such cases.
ISSN:1662-0631
1662-0631
DOI:10.1159/000516199